Form 4: Heartflow Director Wayne Riley Receives Stock Option Grant

Heartflow, Inc. Director Wayne Joseph Riley was granted 23,710 stock options with an exercise price of $19, set to vest by August 2026.

Summary

• Wayne Joseph Riley, a Director of Heartflow, Inc. (HTFL), was granted 23,710 stock options.
• The options have an exercise price of $19 per share.
• The transaction date for this grant was August 7, 2025.
• The options will vest in full on the earlier of Heartflow, Inc.'s annual meeting of shareholders in 2026 or the first anniversary of the grant date (August 7, 2026), subject to continued service.
• The expiration date for these options is August 7, 2035.
• Following this transaction, Mr. Riley beneficially owns 23,710 derivative securities.

Sentiment

Score: 7

Explanation: The grant of stock options to a director is a standard practice for aligning management and board interests with shareholder value, indicating continued commitment. This is generally viewed as a neutral to slightly positive event, as it fosters long-term alignment without directly impacting current financials.

Positives

• The grant of stock options aligns the director's financial interests with those of the shareholders, incentivizing long-term value creation.
• Equity compensation is a standard practice to attract and retain experienced board members.

Future Outlook

The stock option grant includes a vesting schedule that requires continued service through the earlier of Heartflow, Inc.'s annual meeting of shareholders in 2026 or August 7, 2026, indicating an expectation of the director's ongoing commitment to the company.

Industry Context

The grant of stock options to directors is a common form of equity compensation across various industries, including healthcare technology, used to incentivize long-term performance and align the interests of board members with those of shareholders.

Comparison to Industry Standards

• The grant of stock options to directors is a common form of equity compensation across various industries, including healthcare technology, to incentivize long-term performance and align interests with shareholders.
• The vesting schedule, tied to continued service and a specific future date, is typical for such grants, ensuring retention and sustained commitment.
• The exercise price of $19, while not explicitly compared to market price at grant, is a standard feature of stock options.

Stakeholder Impact

• Shareholders: The grant aligns the director's interests with shareholder value creation, potentially leading to more focused long-term decision-making.
• Employees: No direct impact on general employees is indicated by this filing.

Next Steps

• The stock options will vest in full on the earlier of Heartflow, Inc.'s annual meeting of shareholders in 2026 or August 7, 2026, subject to Wayne Joseph Riley's continued service.

Key Dates

Recommendation

This Form 4 reports a routine equity grant to a director, which is a standard compensation practice and does not provide sufficient information to alter an investment thesis or warrant a strong buy/sell recommendation. It primarily serves as a disclosure of insider holdings and compensation.

Keywords

Heartflow, HTFL, stock option, equity grant, director compensation, insider transaction, Form 4